MKSI MKS Instruments Inc.

MKS Instruments Announces Third Quarter 2020 Earnings Conference Call

MKS Instruments Announces Third Quarter 2020 Earnings Conference Call
EN
12/10/2020

Underlying

MKSIMKS Instruments Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MKS Instruments Inc.

Pierre FerraguÊ
  • Pierre FerraguÊ
CON CONTINENTAL AKT...
BMW BAYERISCHE MOTO... ... (+34)

AMD DC GPUs, Arista 2026 guide, Ride-Sharing & Delivery, Autos & Indus...

As always, during earnings season, we wrap-up what happened in the previous week. For our main takes summarized on a single slide, and a few words on each of the names we followed last week, follow the link below.

CON CONTINENTAL AKTIENGESELLSCHAFT
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
QRVO QORVO INC.
LITE LUMENTUM HOLDINGS INC.
ANET ARISTA NETWORKS INC.
QCOM QUALCOMM INC
POWI POWER INTEGRATIONS INC.
ON ON SEMICONDUCTOR CORPORATION
MKSI MKS INSTRUMENTS INC.
MCHP MICROCHIP TECHNOLOGY INCORPORATED
FTNT FORTINET INC.
COHR COHERENT INC.
CDW CDW CORP.
AOSL ALPHA & OMEGA SEMICONDUCTOR
SWKS SKYWORKS SOLUTIONS INC.
3661 ALCHIP TECHNOLOGIES INC.
6963 ROHM CO. LTD.
6201 TOYOTA INDUSTRIES CORP.
LSCC LATTICE SEMICONDUCTOR CORPORATION
AMD ADVANCED MICRO DEVICES INC.
LYFT LYFT
UBER UBER TECHNOLOGIES INC.
FSLY FASTLY
SMCI SUPER MICRO COMPUTER
DASH INC.
ABNB DOORDASH
AEVA AIRBNB INC. CLASS A
RIVN AEVA INC
GRAB RIVIAN AUTOMOTIVE INC
688082 GRAB HLDGS LTD
IONQ ONTO INNOVATION INC.
ARM ACM RESEARCH INC(SHANGHAI)
IONQ INC
ARM HOLDINGS PLC
11/10/25 November 10, 2025 1 EN
 PRESS RELEASE
Free
MKSI MKS Instruments...

MKS Inc. Reports Third Quarter 2025 Financial Results

MKS Inc. Reports Third Quarter 2025 Financial Results Revenue of $988 million, at the high end of guidance GAAP net income of $74 million and net income per diluted share of $1.10, each in the upper half of guidanceAdjusted EBITDA of $240 million and Non-GAAP net earnings per diluted share of $1.93, each in the upper half of guidanceOperating cash flow of $197 million and free cash flow of $147 million, enabling continued focus on the prepayment of debt and reducing net leverage ratio to 3.9x ANDOVER, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- MKS Inc. (NASDAQ: MKSI), a global provider of ...

November 5, 2025 1 EN
 PRESS RELEASE
Free
MKSI MKS Instruments...

MKS Inc. Declares Quarterly Cash Dividend

MKS Inc. Declares Quarterly Cash Dividend ANDOVER, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- MKS Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.22 per share, payable on December 5, 2025, to shareholders of record as of November 24, 2025.  Future dividend declarations, as well as the record and payment dates for such dividends, are subject to the final determination of the Company's Board of Directors. About MKS Inc.MKS Inc. (NASDAQ: MKSI) enables technolog...

November 4, 2025 1 EN
 PRESS RELEASE
Free
MKSI MKS Instruments...

MKS Inc. to Participate in Baird Global Industrial Conference

MKS Inc. to Participate in Baird Global Industrial Conference ANDOVER, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MKS Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today announced that Ram Mayampurath, Executive Vice President and Chief Financial Officer will be presenting at Baird Global Industrial Conference on Tuesday, November 11, 2025 at 3:55 p.m. EST.  A live webcast of the session will be available in the Investor Relations section of the company's website at and a replay of the event will be available for a limited time thereafter. Abou...

November 3, 2025 1 EN
EUR 155.75
MKSI MKS Instruments...

MKS Inc.: Update to credit analysis

Our credit view of this issuer reflects its broad product portfolio with differentiated technology and capabilities, against its end market cyclicality and customer concentration.

MKSI MKS INSTRUMENTS INC.
11/03/25 November 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch